Global Cancer Biomarker Market Size was valued at USD 28.5 Bn in 2024 and is predicted to reach USD 44.5 Bn by 2034 at a 4.7% CAGR during the forecast period for 2025-2034.
The cancer biomarker market is witnessing rapid growth due to increasing cancer incidences and advancements in diagnostic technologies. Biomarkers like PSA, CA125, and BRCA1/2 are crucial for early detection, prognosis, and personalized treatment. Factors such as rising awareness, government initiatives, and investments in R&D are driving market expansion. Additionally, liquid biopsy techniques and next-generation sequencing are gaining prominence for non-invasive and accurate cancer diagnosis.
However, challenges like high costs, stringent regulatory frameworks, and limited specificity hinder market growth. Overall, the cancer biomarker market is poised for significant expansion, propelled by technological advancements and increasing demand for personalized medicine. The increasing incidence of cancer, followed by awareness for early diagnosis, growing investments in research and development of cancer biomarkers, and extensive use of these biomarkers for diagnosis, drug discovery, and development are the key factors for the growth of this market. The COVID-19 pandemic adversely impacted the cancer biomarker market, causing disruptions in supply chains, delayed diagnosis and treatment, and reduced healthcare access. However, the market showed resilience with increased focus on research for COVID-19-related biomarkers and a shift towards telemedicine and remote patient monitoring, driving digital biomarker adoption.
In the cancer biomarker market, segmentation is based on the type of biomarkers and type of cancers. Biomarkers type segmentation includes Human Epidermal Growth Factor Receptor 2 (HER2), Mesenchymal Epithelial Transition (MET), Epidermal Growth Factor Receptor (EGFR), Programmed Death-Ligand 1 (PD-L1), Neurotrophic Tyrosine Receptor Kinase (NTRK), Anaplastic Lymphoma Kinase (ALK) and Other Biomarkers. The types of cancers include breast cancer, prostate cancer, colorectum cancer, lung cancer, thyroid cancer, bladder cancer, melanoma, non-Hodgkin lymphoma, endometrial cancer, kidney cancer, and leukemia.
The HER2 segment in the cancer biomarker market is a key area of focus, particularly in breast cancer diagnostics and treatment. HER2 is overexpressed in around 20% of breast cancers, making it a critical biomarker for prognosis and targeted therapy. The development of HER2-targeted therapies like trastuzumab has significantly improved patient outcomes. Continuous research in HER2 detection methods and personalized treatment strategies further drives growth in this segment.
The breast cancer biomarker segment is pivotal in early detection, prognosis, and personalized treatment of breast cancer. Additionally, novel biomarkers such as circulating tumor DNA (ctDNA) and microRNAs are being explored for their potential to improve diagnostic accuracy and monitor treatment response.
The North America cancer biomarker market is expected to register the highest market share. It can be due to its pharmaceutical industry and technological advancements. Additionally, North America has witnessed a tremendous increase in the adoption of biomarker testing for oncological disorders. The presence of a skilled workforce, advanced infrastructure, and a favorable business environment further results in the region's growth in the cancer biomarker market. In addition, Asia Pacific is estimated to grow at a rapid rate in the global Cancer Biomarker Market due to growing concerns about rapid industrialization, government initiatives, and increasing funding in various industries.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 28.5 Bn |
|
Revenue Forecast In 2034 |
USD 44.5 Bn |
|
Growth Rate CAGR |
CAGR of 4.7% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Biomarkers, Type of Cancer |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Agilent, ARUP Laboratories, BioReference, Foundation Medicine, OncoDNA, Q² Solutions, Thermo Fisher Scientific, YuceBio, Asper Biogene, Caris Life Sciences, CeGaT, Genekor Medical, Guardant Health, Labcorp, MedGenome, NeoGenomics Laboratories, Nonacus, Oxford Gene Technology, Personal Genome Diagnostics, PhenoPath, Positive Biosciences, Quest Diagnostics, and Tempus. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Biomarkers Market Snapshot
Chapter 4. Global Cancer Biomarkers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type of Biomarker Estimates & Trend Analysis
5.1. by Type of Biomarker & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Biomarker:
5.2.1. HER2
5.2.2. MET
5.2.3. EGFR
5.2.4. PD-L1
5.2.5. NTRK
5.2.6. ALK
5.2.7. Novel Biomarkers
5.2.8. Other Biomarkers
Chapter 6. Market Segmentation 2: by Type of Cancer Estimates & Trend Analysis
6.1. by Type of Cancer & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Cancer:
6.2.1. Breast Cancer
6.2.2. Prostate Cancer
6.2.3. Colorectum Cancer
6.2.4. Lung Cancer
6.2.5. Thyroid Cancer
6.2.6. Bladder Cancer
6.2.7. Melanoma
6.2.8. Non-Hodgkins Lymphoma
6.2.9. Endometrial Cancer
6.2.10. Kidney Cancer
6.2.11. Leukemia
Chapter 7. Cancer Biomarkers Market Segmentation 6: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.1.2. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.1.3. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.2.2. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.2.3. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.3.2. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.3.3. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.4.2. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.4.3. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034
7.5.2. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034
7.5.3. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Agilent
8.2.2. ARUP Laboratories
8.2.3. BioReference
8.2.4. Foundation Medicine
8.2.5. OncoDNA
8.2.6. Q² Solutions
8.2.7. Thermo Fisher Scientific
8.2.8. YuceBio
8.2.9. Asper Biogene
8.2.10. Caris Life Sciences
8.2.11. CeGaT
8.2.12. Genekor Medical
8.2.13. Guardant Health
8.2.14. Labcorp
8.2.15. MedGenome
8.2.16. NeoGenomics Laboratories
8.2.17. Nonacus
8.2.18. Oxford Gene Technology
8.2.19. Personal Genome Diagnostics
8.2.20. PhenoPath
8.2.21. Positive Biosciences
8.2.22. Quest Diagnostics
8.2.23. Tempus
Cancer Biomarker Market- By Type of Biomarkers
Cancer Biomarker Market- By Type of Cancer
Cancer Biomarker Market- By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
